FASENRA Israel - English - Ministry of Health

fasenra

astrazeneca (israel) ltd - benralizumab - solution for injection - benralizumab 30 mg / 1 ml - benralizumab - fasenra is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.

ONGLYZA 5 MG Israel - English - Ministry of Health

onglyza 5 mg

astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

ONGLYZA 2.5 MG Israel - English - Ministry of Health

onglyza 2.5 mg

astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 2.5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

ZOLADEX LA Israel - English - Ministry of Health

zoladex la

astrazeneca (israel) ltd - goserelin as acetate - implant for injection - goserelin as acetate 10.8 mg/unit - goserelin - goserelin - prostate cancer suitable for hormonal manipulation.

ZOMIG 2.5 MG Israel - English - Ministry of Health

zomig 2.5 mg

astrazeneca (israel) ltd - zolmitriptan - film coated tablets - zolmitriptan 2.5 mg - zolmitriptan - zolmitriptan - acute treatment of migraine with or without aura.

BUDICORT TURBUHALER 200 MCGDOSE Israel - English - Ministry of Health

budicort turbuhaler 200 mcgdose

astrazeneca (israel) ltd - budesonide - powder for inhalation - budesonide 200 mcg/dose - budesonide - budesonide - bronchial asthma.

BUDICORT TURBUHALER 100 MCGDOSE Israel - English - Ministry of Health

budicort turbuhaler 100 mcgdose

astrazeneca (israel) ltd - budesonide - powder for inhalation - budesonide 100 mcg/dose - budesonide - budesonide - bronchial asthma.